FY26 Annual Report

Key points

• Revenues up 25.6% to $788.7m
• Operating EBITDA up 30.3% to $164.8m
• Statutory NPAT up 677% to $22.0m
• Total dividend increased to 9.3 cents per share
• New leadership team appointed

Full summary

Integral Diagnostics Ltd (IDX) reported a robust performance for the full year ended 30 June 2026. The company achieved revenues of $788.7 million, up 25.6% from the previous year, and an operating EBITDA of $164.8 million, up 30.3%. Statutory net profit after tax (NPAT) surged 677% to $22.0 million. The company also declared a fully franked final dividend of 6.0 cents per share, bringing the total dividend for FY26 to 9.3 cents per share. The company expanded its presence through the merger with Capitol Health and invested in growth areas such as teleradiology and specialist orthopaedic hospitals. A new leadership team was appointed to drive future growth and operational excellence.